ALDA Pharmaceuticals Corp.
TSX VENTURE : APH

ALDA Pharmaceuticals Corp.

August 04, 2006 16:30 ET

ALDA Grants Incentive Stock Options

VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - Aug. 4, 2006) - ALDA Pharmaceuticals Corp. (TSX VENTURE:APH) (the "Company" or "ALDA") announces that it has granted incentive stock options to certain directors, senior officers, employees and consultants to purchase an aggregate of 1,880,000 common shares at an exercise price of $0.10. 1,580,000 of the foregoing incentive stock options have a term of two years, expiring on August 2, 2008 and 300,000 of the foregoing incentive stock options granted to a consultant to the Company have a term of five years, expiring on August 2, 2011, but are subject to vesting on certain milestones. Options granted to consultants performing investor relations services to the Company will be subject to further vesting over the first twelve months after the grant in accordance with TSX Venture Exchange policy. The options and shares issuable upon exercise, if any, will be subject to a four-month hold period from the date of grant in accordance with TSX Venture Exchange policy. The grant was pursuant to the Company's Rolling Stock Option Plan, which was re-affirmed by the shareholders of the Company on December 13, 2005 and subsequently accepted by the Exchange.

About ALDA Pharmaceuticals Corp.

ALDA has developed and markets wide spectrum, non-toxic, non-corrosive, biodegradable infection control products based on its patent-pending T(3)6® technology. Its lead product, T(3)6® Disinfectant, is acknowledged to be effective against all bacteria and viruses including Avian Flu, SARS, Norwalk Virus, HIV, Legionella and Hepatitis because of its ability to kill polio and TB.


The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information

  • ALDA Pharmaceuticals Corp.
    Terrance G. Owen, Ph.D., MBA
    President, CEO and Director
    or
    ALDA Pharmaceuticals Corp.
    Aaron Genereaux
    Distribution & Sales Contact
    (604) 521-8300
    aaron@aldacorp.com
    or
    ALDA Pharmaceuticals Corp.
    Scott Young
    Investor Relations Contact
    (604) 288-7222
    scott_young@aldacorp.com
    www.aldacorp.com